ChiraLig™ Products Separate Individual Enantiomeric Species at a High Purity Level
The ChiraLig™ MRT™ Process Provides Higher Purity at Lower Cost
- Low process operating costs due to fewer separation stages, simplicity of the process, and low consumption of operating chemicals
- Low capital costs due to reduced floor space, lower equipment cost, and decreased plant complexity
- Extension of drug intellectual property (IP) lifetime due to use of proprietary ChiraLig™ MRT™ chemistry and separation processes
- Reduction in the time required for drug introduction into the market due to high product throughput
- Operation using either aqueous or non-aqueous feed streams due to the versatility of the process
- Elimination of the need for downstream purification steps due to the combination of both enantio- and chemo-separations in one process step